Back to Results
First PageMeta Content
Interferon / Ribavirin / Biology / Hepatitis / Medicine / Antivirals / Cytokines / Boceprevir


The Changing Face of Hepatitis C Treatment Nezam H. Afdhal M.D Professor of Medicine, Harvard Medical School, Chief of Hepatology,
Add to Reading List

Document Date: 2013-04-25 10:17:29

Open Document

File Size: 2,66 MB

Share Result on Facebook

City

San Francisco / /

Company

Novartis / Merck / Medgenics In / Vertex / BOC / High RVR / Springbank / Ligand / /

Event

FDA Phase / /

Facility

Beth Israel Deaconess Medical Center / /

IndustryTerm

communications firms / pharmaceutical organizations / mg / Hepatitis C Treatment / /

MedicalCondition

*Anemia / CHC / disease / dysgeusia / neutropenia / HCV / Obesity / anemia / HCV genotype / HCV RNA / /

Organization

Harvard Medical School / US Food and Drug Administration / Antiviral Drugs Advisory Committee / Beth Israel Deaconess Medical Center / /

Person

Hyperbilirubinemia / Silver Spring / Kadmon / Beth Israel / /

Position

speaker / consultant / Chief / Professor of Medicine / Chief of Hepatology / /

Product

Boceprevir capsules / RVR / HMS / Ribavirin / Peginterferon / G1 / /

ProvinceOrState

Connecticut / /

Technology

genotype / /

SocialTag